Package: 500mg (3 pills)
Azab 500 – a representative of a new group of macrolide antibiotics – azalides. It has a wide spectrum of antibacterial (bacteriostatic) action. In high concentrations acts bactericidal.
Pharmacologic effect of Azab 500
The antimicrobial effect is due to binding to the 508 subunit of the ribosomes, inhibition of the peptidranslokase in the translation stage and suppression of the protein biosynthesis, which leads to a slowing of the growth and multiplication of bacteria.
Pharmacokinetics of Azab 500
When ingested quickly absorbed from the digestive tract (which is due to the stability of Azithromycin in an acidic medium and its lipophilicity). After oral administration at a dose of 500 mg, the maximum concentration in the blood serum is achieved after 2.5-3 hours and is 0.4 mg / l. Bioavailability is 37%. It penetrates well into the respiratory tract, organs and tissues of the urogenital tract (in particular, into the prostate gland), into the skin and soft tissues. Concentration in tissues is 10-50 times higher than in serum. High concentration in tissues and a long half-life are due to low binding of azithromycin to blood plasma proteins, as well as its ability to penetrate into eukaryotic cells and to concentrate in a medium with a low pH in lysosomes. This in turn assumes a large volume of distribution (31.1 l / kg) and high plasma clearance.
Indications for use
Infectious-inflammatory diseases caused by microorganisms sensitive to the preparation:
- infection of the upper respiratory tract and JIOP organs (angina, pharyngitis, sinusitis, tonsillitis, otitis media);
- infection of the lower respiratory tract (bacterial and atypical pneumonia, acute bronchitis, chronic bronchitis in the acute stage);
- infections of the skin and soft tissues: migratory chronic erythema (the initial stage of Lyme disease), erysipelas, impetigo, pyoderma;
- infection of the urogenital tract (uncomplicated urethritis and / or cervicitis, colpitis), including urogenital chlamydia;
diseases of the stomach and duodenum, associated with Helicobacter pylori (as part of a combination therapy).